Evidence-based Guideline for Therapeutic Drug Monitoring of Vancomycin: 2020 Update by the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society

Abstract

Background Clinical practice guidelines or recommendations often require timely and regular updating as new evidence emerges, because this can alter the risk-benefit trade-off. The scientific process of developing and updating guidelines accompanied by adequate implementation can improve outcomes. To promote better management of patients receiving vancomycin therapy, we updated the guideline for the therapeutic drug monitoring (TDM) of vancomycin published in 2015. Methods Our updated recommendations complied with standards for developing trustworthy guidelines, including timeliness and rigor of the updating process, as well as the use of the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. We also followed the methodology handbook published by the National Institute for Health and Clinical Excellence and the Spanish National Health System. Results We partially updated the 2015 guideline. Apart from adults, the updated guideline also focuses on pediatric patients and neonates requiring intravenous vancomycin therapy. The guideline recommendations involve a broadened range of patients requiring TDM, modified index of TDM (both 24-hour area under the curve and trough concentration), addition regarding the necessity and timing of repeated TDM, and initial dose for specific subpopulations. Overall, 1 recommendation was deleted and 3 recommendations were modified. Eleven new recommendations were added, and no recommendation was made for 2 clinical questions. Conclusions We updated an evidence-based guideline regarding the TDM of vancomycin using a rigorous and multidisciplinary approach. The updated guideline provides more comprehensive recommendations to inform rational and optimized vancomycin use and is thus of greater applicability.

Staphylococcus aureus ventilator-associated pneumonia in patients with COVID-19: clinical features and potential inference with lung dysbiosis

“…On the other hand, extensive antibiotic treatments in COVID-19 patients [ 47 ] may perturb gut homeostasis, allowing bacterial pathogens to cause pneumonia or other invasive infections [ 48 ]. Consistent with a significantly altered gut microbiota of COVID-19 patients compared to healthy controls [ 49 ], our 16S rRNA gene sequencing data show that the lung bacterial community of patients with COVID-19 was different from that of patients without COVID-19 ( P = 0.004). Interestingly, Olsenella and Streptococcus anginosus , which normally inhabit the oropharynx forming biofilm to enhance bacterial adherence and thriving [ 50 ], were among the taxa significantly enriched in the COVID-19 lung microbiota together with SA.…”

Health-related quality of life issues, including symptoms, in patients with active COVID-19 or post COVID-19; a systematic literature review

“…Despite COVID-19 being a novel disease, in this review, there was very good representation of patients from different care-settings and age groups, with several different comorbidities. The reports included both females and males, with the exception of some case reports and a few studies on gender-specific populations such as patients in a maternity ward [ 39 ]. Reports from China, the first country to publish descriptions on COVID-19-specific symptoms, focused on core symptoms such as fever, cough, shortness of breath and diarrhoea and a large proportion of patients across all ages needed hospital admission and intensive care.…”

Host factors facilitating SARS‐CoV‐2 virus infection and replication in the lungs

“…A study on 30 patients with COVID-19 also showed that the gut microbiome was associated with a dysbiosis compared to healthy controls. COVID-19 patients showed a significantly reduced bacterial diversity due to an overgrowth of opportunistic pathogens ( Streptococcus , Rothia , Veillonella and Actinomyces ) and a decrease of beneficial symbionts [ 246 ]. Another group worked on the transcriptional activity of SARS-CoV-2 in the feces of 15 patients with COVID-19 and showed that the gut microbiome was correlated to the viral transcriptional activity [ 247 ].…”